vs
CytomX Therapeutics, Inc.（CTMX）与RBB Bancorp（RBB）财务数据对比。点击上方公司名可切换其他公司
RBB Bancorp的季度营收约是CytomX Therapeutics, Inc.的1.7倍（$32.3M vs $18.7M），RBB Bancorp净利率更高（31.5% vs -0.8%，领先32.3%），RBB Bancorp同比增速更快（12.6% vs -25.7%），RBB Bancorp自由现金流更多（$42.6M vs $-15.8M），过去两年RBB Bancorp的营收复合增速更高（7.0% vs -15.9%）
CytomX Therapeutics是一家临床阶段生物技术公司，专注于创新癌症免疫疗法研发，依托专有的Probody技术平台开发仅在肿瘤微环境中激活的靶向疗法，可降低脱靶毒性，管线覆盖多种实体瘤适应症，还与全球头部药企合作推进相关治疗方案开发。
RBB银行控股公司是总部位于美国的金融控股集团，旗下核心主体为皇家商业银行，主要服务亚裔社群、中小微企业、不动产投资者及零售客户，提供商业信贷、储蓄存款、财富管理等多元金融服务，业务覆盖美国沿海核心都会区。
CTMX vs RBB — 直观对比
营收规模更大
RBB
是对方的1.7倍
$18.7M
营收增速更快
RBB
高出38.3%
-25.7%
净利率更高
RBB
高出32.3%
-0.8%
自由现金流更多
RBB
多$58.4M
$-15.8M
两年增速更快
RBB
近两年复合增速
-15.9%
损益表 — Q2 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $18.7M | $32.3M |
| 净利润 | $-154.0K | $10.2M |
| 毛利率 | — | — |
| 营业利润率 | -6.9% | 39.5% |
| 净利率 | -0.8% | 31.5% |
| 营收同比 | -25.7% | 12.6% |
| 净利润同比 | 97.6% | 132.1% |
| 每股收益（稀释后） | — | $0.59 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CTMXRBB
| Q4 25 | — | $32.3M | ||
| Q3 25 | — | $32.6M | ||
| Q2 25 | $18.7M | $35.8M | ||
| Q1 25 | $50.9M | $28.5M | ||
| Q4 24 | $38.1M | $28.7M | ||
| Q3 24 | $33.4M | $30.3M | ||
| Q2 24 | $25.1M | $27.5M | ||
| Q1 24 | $41.5M | $28.2M |
净利润CTMXRBB
| Q4 25 | — | $10.2M | ||
| Q3 25 | — | $10.1M | ||
| Q2 25 | $-154.0K | $9.3M | ||
| Q1 25 | $23.5M | $2.3M | ||
| Q4 24 | $18.9M | $4.4M | ||
| Q3 24 | $5.7M | $7.0M | ||
| Q2 24 | $-6.5M | $7.2M | ||
| Q1 24 | $13.8M | $8.0M |
营业利润率CTMXRBB
| Q4 25 | — | 39.5% | ||
| Q3 25 | — | 40.7% | ||
| Q2 25 | -6.9% | 36.1% | ||
| Q1 25 | 44.4% | 11.2% | ||
| Q4 24 | 46.4% | 17.6% | ||
| Q3 24 | 12.3% | 31.6% | ||
| Q2 24 | -33.7% | 35.6% | ||
| Q1 24 | 28.1% | 39.9% |
净利率CTMXRBB
| Q4 25 | — | 31.5% | ||
| Q3 25 | — | 31.2% | ||
| Q2 25 | -0.8% | 26.1% | ||
| Q1 25 | 46.2% | 8.0% | ||
| Q4 24 | 49.6% | 15.3% | ||
| Q3 24 | 17.2% | 23.1% | ||
| Q2 24 | -26.0% | 26.4% | ||
| Q1 24 | 33.3% | 28.4% |
每股收益（稀释后）CTMXRBB
| Q4 25 | — | $0.59 | ||
| Q3 25 | — | $0.59 | ||
| Q2 25 | — | $0.52 | ||
| Q1 25 | — | $0.13 | ||
| Q4 24 | — | $0.26 | ||
| Q3 24 | — | $0.39 | ||
| Q2 24 | — | $0.39 | ||
| Q1 24 | — | $0.43 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $49.0M | $212.3M |
| 总债务越低越好 | — | $119.9M |
| 股东权益账面价值 | $119.9M | $523.4M |
| 总资产 | $175.1M | $4.2B |
| 负债/权益比越低杠杆越低 | — | 0.23× |
8季度趋势，按日历期对齐
现金及短期投资CTMXRBB
| Q4 25 | — | $212.3M | ||
| Q3 25 | — | $234.9M | ||
| Q2 25 | $49.0M | $191.9M | ||
| Q1 25 | $47.6M | $238.8M | ||
| Q4 24 | $38.1M | $257.7M | ||
| Q3 24 | $40.6M | $349.4M | ||
| Q2 24 | $43.2M | $252.8M | ||
| Q1 24 | $36.2M | — |
总债务CTMXRBB
| Q4 25 | — | $119.9M | ||
| Q3 25 | — | $119.8M | ||
| Q2 25 | — | $119.7M | ||
| Q1 25 | — | $119.6M | ||
| Q4 24 | — | $119.5M | ||
| Q3 24 | — | $119.4M | ||
| Q2 24 | — | $119.3M | ||
| Q1 24 | — | $119.2M |
股东权益CTMXRBB
| Q4 25 | — | $523.4M | ||
| Q3 25 | — | $514.3M | ||
| Q2 25 | $119.9M | $517.7M | ||
| Q1 25 | $25.0M | $510.3M | ||
| Q4 24 | $-456.0K | $507.9M | ||
| Q3 24 | $-23.5M | $509.7M | ||
| Q2 24 | $-31.2M | $511.3M | ||
| Q1 24 | $-31.7M | $514.0M |
总资产CTMXRBB
| Q4 25 | — | $4.2B | ||
| Q3 25 | — | $4.2B | ||
| Q2 25 | $175.1M | $4.1B | ||
| Q1 25 | $98.5M | $4.0B | ||
| Q4 24 | $120.5M | $4.0B | ||
| Q3 24 | $139.0M | $4.0B | ||
| Q2 24 | $159.2M | $3.9B | ||
| Q1 24 | $184.7M | $3.9B |
负债/权益比CTMXRBB
| Q4 25 | — | 0.23× | ||
| Q3 25 | — | 0.23× | ||
| Q2 25 | — | 0.23× | ||
| Q1 25 | — | 0.23× | ||
| Q4 24 | — | 0.24× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.23× | ||
| Q1 24 | — | 0.23× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-15.8M | $43.4M |
| 自由现金流经营现金流 - 资本支出 | $-15.8M | $42.6M |
| 自由现金流率自由现金流/营收 | -84.6% | 131.8% |
| 资本支出强度资本支出/营收 | 0.1% | 2.5% |
| 现金转化率经营现金流/净利润 | — | 4.26× |
| 过去12个月自由现金流最近4个季度 | $-77.7M | $73.5M |
8季度趋势，按日历期对齐
经营现金流CTMXRBB
| Q4 25 | — | $43.4M | ||
| Q3 25 | — | $2.1M | ||
| Q2 25 | $-15.8M | $21.7M | ||
| Q1 25 | $-21.0M | $7.8M | ||
| Q4 24 | $-19.9M | $58.5M | ||
| Q3 24 | $-20.7M | $24.5M | ||
| Q2 24 | $-19.5M | $11.7M | ||
| Q1 24 | $-26.0M | $4.8M |
自由现金流CTMXRBB
| Q4 25 | — | $42.6M | ||
| Q3 25 | — | $1.8M | ||
| Q2 25 | $-15.8M | $21.6M | ||
| Q1 25 | $-21.2M | $7.6M | ||
| Q4 24 | $-20.0M | $57.7M | ||
| Q3 24 | $-20.7M | $24.2M | ||
| Q2 24 | $-19.6M | $11.5M | ||
| Q1 24 | $-26.2M | $4.7M |
自由现金流率CTMXRBB
| Q4 25 | — | 131.8% | ||
| Q3 25 | — | 5.4% | ||
| Q2 25 | -84.6% | 60.2% | ||
| Q1 25 | -41.6% | 26.7% | ||
| Q4 24 | -52.5% | 201.0% | ||
| Q3 24 | -62.1% | 80.0% | ||
| Q2 24 | -78.2% | 42.0% | ||
| Q1 24 | -63.1% | 16.6% |
资本支出强度CTMXRBB
| Q4 25 | — | 2.5% | ||
| Q3 25 | — | 1.1% | ||
| Q2 25 | 0.1% | 0.3% | ||
| Q1 25 | 0.2% | 0.6% | ||
| Q4 24 | 0.2% | 2.7% | ||
| Q3 24 | 0.1% | 0.8% | ||
| Q2 24 | 0.4% | 0.5% | ||
| Q1 24 | 0.3% | 0.5% |
现金转化率CTMXRBB
| Q4 25 | — | 4.26× | ||
| Q3 25 | — | 0.21× | ||
| Q2 25 | — | 2.32× | ||
| Q1 25 | -0.89× | 3.39× | ||
| Q4 24 | -1.05× | 13.34× | ||
| Q3 24 | -3.61× | 3.50× | ||
| Q2 24 | — | 1.61× | ||
| Q1 24 | -1.89× | 0.60× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
RBB
暂无分部数据
